Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: Interpretation of false-positive results

Journal of B.U.ON.

Volumn 12, Issue 4, 2007, Pages 487-492

  Zervoudis, Stephane ^a   Peitsidis, P ^b   Iatrakis, G ^c   Panourgias, E ^d   Koureas, A ^e   Navrozoglou, I ^a   Dubois, J B ^f  

^a UNIVERSITY OF IOANNINA   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF WEST ATTICA   (Greece)

^d 2nd Department of Radiology   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

^f UNIV MONTPELLIER   (France)

Author keywords

Breast cancer; CA 15.3; CA 27 29; CEA; TPA; TPS; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ARTICLE; BONE SCINTISCANNING; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; ECHOMAMMOGRAPHY; FALSE POSITIVE RESULT; FOLLOW UP; HEPATITIS; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; METASTASIS; NEPHROLITHIASIS; OVARY CYST; PROTEIN BLOOD LEVEL; SARCOIDOSIS; THYROID DISEASE;

BREAST NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 38349112343     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005; 16: 481-488.
2. Dubois JB, Grenier J (Eds). Les marqueurs tumoraux (3rd edn). Editions Espaces 2000.
3. Duffy MJ. Evidence for the clinical use of tumor markers. Ann Clin Biochem 2004; 41: 370-377.
4. Norton JA. Carcinoembryonic Antigen: New applications for an old marker. Ann Surg 1991; 213: 95-97.
5. Lauro S, Trasatti L, Bordin F et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 1999; 19: 3511-3515.
6. McLaughlin R, McGrath J, Grimes H, Given HF. The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 2000; 15: 340-342.
7. Collazos J, Genolla J, Ruibal A. CA 15.3 in nonmalignant liver diseases. Int J Biol Markers 1991; 6: 188-192.
8. Cases A, Filella X, Molina R, Ballesta AM, Lopez-Pedret J, Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991; 57: 183-186.
9. Canizares F, Sola J, Perez M et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol 2001; 22: 273-281.
10. Molina R, Jo J, Fillela X et al. C-erbB-2 oncoprotein, CEA and CA 15-3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998; 51: 109-119.
11. Guadagni F, Ferroni P, Carlini S et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001; 7: 2357-2362.
12. Collazos J, Genolla J, Ruibal A. Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients. Int J Biol Markers 1992; 7: 244-248.
13. Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res 1993; 53: 1788-1793.
14. Kushlinskii NE, Gershtein ES, Kazantseva IA et al. Plasminogen activators of urokinase and tissue types and their inhibitor (PAT-1) in cytosol fraction in thyroid diseases. Vestn Ross Akad Med Nauk 2001; 5: 32-34 (in Russian with Engl abstr).
15. Tutluoglu B, Gurel CB, Ozdas SB et al. Platelet function and fibrinolytic activity in patients with bronchial asthma. Clin Appl Thromb Hemost 2005; 11: 77-81.
16. Posan E, Tornai I, Udvardy M. Fibrinolysis in chronic liver diseases studied by in vitro blood coagulation tests. Orv Hetil 1994; 135: 2821-2824 (in Hungarian with Engl abstr).
17. Frenette PS, Thirlwell MP, Trudeau M, Thomson DM, Joseph L, Shuster JS. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancy. Tumour Biol 1994; 15: 247-254.
18. Martinez L, Castilla JA, Blanco N, Peran F, Herruzo A. CA 125, CA 15.3, CA 27.29, CEA, beta-hCG and alpha-fetoprotein levels in cyst fluid of breast macrocysts. Int J Gynaecol Obstet 1995; 48: 187-192.
19. Martinazzi M, Crivelli F, Grassi C, Zampatti C. Immunohistochemical distribution of mucinous-like carcinoma associated antigen (MCA) in breast and non-breast cancer: comparison with other biological parameters. Int J Biol Markers 1990; 5: 138-144.
20. Hanzal E, Kolbl H, Gitsch G, Bieglmayer C. Mucinous carcinoma-associated antigen (MCA) in ovarian cancer. Gynekol Rundsch 1990; 30 (Suppl 1): 68-70.
21. Van Dalen A. TPS monitoring in metastatic breast cancer. Int J Biol Markers 1999; 14: 45-48.
22. Shabana A, Onsrud M. Tissue polypeptide-specific antigen and CA-125 as serum markers in ovarian carcinoma. Tumour Biol 1994; 15: 361-367.
23. Yedema KA, Kenemans P, Wobbes T et al. Carcinoma-associated mucin serum markers CAM26 and CAM29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovar, endometrium and cervix. Int J Cancer 1991; 47: 170-179.
24. Gonzalez-Quintela A, Mallo N, Mella C et al. Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases. Liver Int 2006; 26: 1217-1224.
25. Devarbhavi H, Kaese D, Williams AW, Rakela J, Klee GG, Kamath PS. Cancer antigen 125 in patients with chronic liver disease. Mayo Clin Proc 2002; 77: 538-541.
26. Di Seri M, Manna A, Scio M, Marchei GG, De Benedetto A, Reale MG. Evaluation of the new marker CA 549 versus CA 15-3 in neoplastic and non-neoplastic disease of the breast. J Nucl Med Allied Sci 1990; 34 (4 Suppl): 49.
27. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B, Estenoz-Alfaro J. Diagnostic value of CA 549 in pleural fluid: Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer 2003; 40: 289-294.
28. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003; 68: 1075-1082.
29. Shering SG, Sherry F, Mc Dermott EW, O'Higgins NJ, Duffy MJ. Preoperative CA 15-3 concentrations predict outcome in patients with breast carcinoma. Cancer 1998; 83: 2521-2527.
30. Kumplulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15-3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002; 76: 95-102.
31. Gion M, Boracchi P, Dittadi R et al. Prognostic role of serum CA 15-3 in 362 node-negative breast cancers: an old player for a new game. Eur J Cancer 2002; 38: 1181-1188.
32. Jiskra J, Limanova Z, Barkmanova J, Smutek D, Friedmannova Z. Autoimmune thyroid diseases in women with breast cancer and colorectal cancer. Physiol Res 2004; 53: 693-702.
33. Huang Y, Zimmerman RL, Bibbo M. Diagnostic value of CA 15-3 antibody in detecting metastatic adenocarcinoma. Ann Quant Cytol Histol 2004; 26: 259-262.
34. Clinton SR, Beason KL, Bryant S et al. A comparative study of four serological tumor markers for the detection of breast cancer. Biomed Sci Instrum 2003; 39: 408-414.